PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-35.13%
Negative ROE while Drug Manufacturers - Specialty & Generic median is -0.15%. Seth Klarman would investigate if capital structure or industry issues are at play.
-27.33%
Negative ROA while Drug Manufacturers - Specialty & Generic median is -1.32%. Seth Klarman would consider if assets are underutilized or if it’s a distressed opportunity.
-30.89%
Negative ROCE while Drug Manufacturers - Specialty & Generic median is -0.27%. Seth Klarman would investigate whether a turnaround is viable.
-8.04%
Negative gross margin while Drug Manufacturers - Specialty & Generic median is 49.16%. Seth Klarman would check if the firm is selling below cost.
-828.86%
Negative operating margin while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would look for a path to operational turnaround.
-821.32%
Negative net margin while Drug Manufacturers - Specialty & Generic median is -2.30%. Seth Klarman would see if cost cuts or revenue growth can fix losses.